BGLC

BioNexus Gene Lab Corp.
CAPPED RATING

BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of Covid-19, Dengue, human immunodeficiency virus, human papillomavirus, and the risk potentiality of cancers diseases. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming.

BioNexus Gene Lab Corp. (BGLC) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Basic Materials sector peers. Its strongest pillar is Value (B); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
B
Factor Score 3.4 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
D-
Factor Score 0.9 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA 0.3
Rev Growth YoY -96.6%
Gross Margin 12.3%
Price Return 3M -46.8%
Price Return 12M -81.9%
Catalyst Signal 0.00
Market Cap $2.4M
TTM Revenue $3.1M
Price / Sales 0.8
ROE -33.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.4) F (0.6) D+ (1.7) D- (0.9) C+ (2.5) D+ (1.8)
2026-11-10 B (3.4) F (0.6) D+ (1.7) D (1.2) C+ (2.5) C- (1.9)
2026-11-03 B (3.4) F (0.5) D+ (1.7) D (1.3) C+ (2.6) C- (1.9)
2026-10-27 B- (3.0) F (0.6) D+ (1.6) D+ (1.6) C+ (2.7) C- (1.9)
2026-10-20 B- (3.0) F (0.6) D+ (1.6) D (1.3) C+ (2.7) C- (1.9)
Page 1 of 4